Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PRNP | P04156 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695307 | 0.92 | CDK1 (0.73) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL18290322 | 0.88 | FERMT2 (0.64) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL13999523 | 0.86 | HTR1A (0.76) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL18290329 | 0.86 | FERMT2 (0.62) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL1147601 | 0.85 | KDM4E (0.84) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL706339 | 0.85 | CDK1 (0.64) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL12871542 | 0.85 | KDM4E (0.61) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL1147663 | 0.84 | KDM4E (0.82) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL12871599 | 0.84 | KDM4E (0.60) | KDM4ELMNAHTTHSD17B10FERMT2 | |
| SCHEMBL1147600 | 0.84 | KDM4E (0.82) | KDM4ELMNAHTTHSD17B10FERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| WO-2026102333-A1 | METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735051-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720081-A1 | CONJUGATE COMPOSITIONS COMPRISING PHOSPHORYL GUANIDINE LINKAGES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-121586719-A | Conjugate compositions comprising guanidine phosphate linkages and uses thereof | 艾维迪提生物科学公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | KOSAK KENNETH M | 2007-07-19 | — | — | US | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | KDM4E 1810/4885LMNA 1079/4885HTT 3872/4885 |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | GPR119, CLTA, CHMP4B | KDM4E 3099/4885LMNA 1595/4885HTT 927/4885 |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | KDM4E 2153/4885LMNA 491/4885HTT 1013/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | KDM4E 3418/4885LMNA 159/4885HTT 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.